TY - JOUR
T1 - Mitotic centromere-associated kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer
AU - Ishikawa, K.
AU - Kamohara, Y.
AU - Tanaka, F.
AU - Haraguchi, N.
AU - Mimori, K.
AU - Inoue, H.
AU - Mori, M.
N1 - Funding Information:
We thank Dr Y Nakamura, Ms T Shimooka, Ms K Ogata, Ms M Kasagi and Ms Y Nakagawa for their technical assistance and advice. This work was supported in part by the following grants and foundations: CREST, Japan Science and Technology Agency; Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research, grants 17109013, 17591411, 17591413, 18390367, 18590333, 18659384, 18790964, 19890336 and 19591509; The Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research on Priority Areas, Grant 18015039; Third Term Comprehensive Ten-Year Strategy for Cancer Control, Grant 16271201.
PY - 2008/6/3
Y1 - 2008/6/3
N2 - Mitotic centromere-associated kinesin (MCAK) is a microtubule depolymerase that is essential for proper kinetochore-microtubule attachment during spindle formation. Overexpression of MCAK has been correlated with aggressive forms of carcinoma, resulting in poor prognosis of colorectal cancer. The purpose of this study was to quantify MCAK expression in malignant and benign colorectal tissues and to determine if MCAK expression levels correlate with clinicopathologic factors and prognosis in colorectal cancer patients. Paired colorectal tissue samples from tumours and the corresponding normal tissues were obtained from 120 patients with colorectal cancer who underwent surgical resection. The real-time reverse transcriptase-PCR and immunohistochemistry were used to analyse mRNA and protein expression status with respect to various clinicopathological factors. MCAK expression was higher in colorectal cancer tissue (P<0.01) than in corresponding normal tissue, and this elevated expression level was markedly associated with factors such as lymph node metastasis (P=0.0023), venous invasion (P=0.019), peritoneal dissemination (P=0.021) and Dukes' classification (P=0.0023). Patients with high MCAK mRNA expression also showed a far poorer survival rate than those with low MCAK mRNA expression (P<0.01). Elevated MCAK expression was an independent predictor of overall survival and lymph node metastasis. These data suggest that MCAK expression may serve as a good marker of prognosis and lymph node metastasis in colorectal cancer.
AB - Mitotic centromere-associated kinesin (MCAK) is a microtubule depolymerase that is essential for proper kinetochore-microtubule attachment during spindle formation. Overexpression of MCAK has been correlated with aggressive forms of carcinoma, resulting in poor prognosis of colorectal cancer. The purpose of this study was to quantify MCAK expression in malignant and benign colorectal tissues and to determine if MCAK expression levels correlate with clinicopathologic factors and prognosis in colorectal cancer patients. Paired colorectal tissue samples from tumours and the corresponding normal tissues were obtained from 120 patients with colorectal cancer who underwent surgical resection. The real-time reverse transcriptase-PCR and immunohistochemistry were used to analyse mRNA and protein expression status with respect to various clinicopathological factors. MCAK expression was higher in colorectal cancer tissue (P<0.01) than in corresponding normal tissue, and this elevated expression level was markedly associated with factors such as lymph node metastasis (P=0.0023), venous invasion (P=0.019), peritoneal dissemination (P=0.021) and Dukes' classification (P=0.0023). Patients with high MCAK mRNA expression also showed a far poorer survival rate than those with low MCAK mRNA expression (P<0.01). Elevated MCAK expression was an independent predictor of overall survival and lymph node metastasis. These data suggest that MCAK expression may serve as a good marker of prognosis and lymph node metastasis in colorectal cancer.
UR - http://www.scopus.com/inward/record.url?scp=44349151502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44349151502&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6604379
DO - 10.1038/sj.bjc.6604379
M3 - Article
C2 - 18506187
AN - SCOPUS:44349151502
SN - 0007-0920
VL - 98
SP - 1824
EP - 1829
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 11
ER -